Berenberg Issues a Downgrade on Shire plc (SHPG) Shares. What’s Next?

September 8, 2018 - By Mark Babin

Shire plc (NASDAQ:SHPG) Logo

Shire plc (SHPG) Receives a Downgrade

The old rating for Shire plc (SHPG) shares of a Buy has been discontinued, as stock research analysts at Berenberg decreased the current rating for Shire plc (SHPG) shares to a Hold.

The stock decreased 1.05% or $1.77 during the last trading session, reaching $166.29. About 1.13M shares traded or 49.71% up from the average. Shire plc (SHPG) has declined 10.60% since September 8, 2017 and is downtrending. It has underperformed by 23.17% the S&P500.

Analysts await Shire plc (NASDAQ:SHPG) to report earnings on October, 26. They expect $3.67 EPS, down 3.67 % or $0.14 from last year’s $3.81 per share. SHPG’s profit will be $1.11 billion for 11.33 P/E if the $3.67 EPS becomes a reality. After $3.88 actual EPS reported by Shire plc for the previous quarter, Wall Street now forecasts -5.41 % negative EPS growth.

Shire plc, a biotechnology company, focused on serving people with rare diseases and other specialized conditions worldwide. The company has market cap of $50.20 billion. The firm offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. It has a 10.51 P/E ratio. The Company’s marketed products include ADVATE and ADYNOVATE/ADYNOVI for hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand Disease; FEIBA to treat hemophilia A and B patients with inhibitors; CINRYZE and FIRAZYR for hereditary angioedema; ELAPRASE to treat hunter syndrome; REPLAGAL for Fabry disease; and VPRIV to treat type 1 Gaucher disease.

More notable recent Shire plc (NASDAQ:SHPG) news were published by: which released: “Shire acquires Sanaplasma AG boosting plasma collection network for immunology franchise” on September 06, 2018, also with their article: “5 Health Care Stocks in Gurus’ Portfolios” published on September 06, 2018, published: “Premarket analyst action – healthcare” on September 07, 2018. More interesting news about Shire plc (NASDAQ:SHPG) were released by: and their article: “Shire Completes Sale of Oncology Franchise” published on August 31, 2018 as well as‘s news article titled: “Tracking Larry Robbins’ Glenview Capital Management Portfolio – Q2 2018 Update” with publication date: September 03, 2018.

Shire plc (NASDAQ:SHPG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.